OncLive® On Air

In today’s episode, our discussion features Eric Whitman, MD; and Vishal Patel, MD, FAAD, FACMS. Dr Whitman is medical director of the oncology service line with Atlantic Health System in Morristown, New Jersey. Dr Patel is an associate professor of dermatology and medicine at the GW School of Medicine & Health Sciences, as well as the director of the Cutaneous Oncology Program at the GW Cancer Center in Washington, DC. 
In our exclusive interview, Drs Whitman and Patel discussed the evolving treatment paradigm for patients with cutaneous squamous cell carcinoma (CSCC), emphasizing the role of neoadjuvant and adjuvant immunotherapies like cemiplimab and pembrolizumab. They noted that key factors for surgical candidacy include tumor size, location, and patient factors like age and comorbidities. They also emphasized that multidisciplinary collaboration is crucial for optimal outcomes. Furthermore, they highlighted future directions for CSCC management, including personalized medicine, genetic testing for recurrence risk, and expanding immunotherapy use to immunosuppressed patients. They also noted that ongoing trials aim to optimize treatment doses and explore new immunotherapy combinations.

In today’s episode, the discussion features Komal Jhaveri, MD, FACP, a breast medical oncologist at Memorial Sloan Kettering Cancer Center, who reviewed the evolving role of TROP2-directed antibody–drug conjugates (ADCs) in the management of hormone receptor (HR)–positive, HER2-negative metastatic breast cancer. She drew on findings from the phase 3 ASCENT-07 trial (NCT05840211), which evaluated sacituzumab govitecan-hziy (Trodelvy) in the first-line setting following endocrine therapy for patients with HR-positive, HER2-negative metastatic breast cancer.
In this exclusive interview, Dr Jhaveri discussed the rationale for evaluating sacituzumab govitecan earlier in the treatment paradigm, summarized key efficacy outcomes from ASCENT-07, and contextualized why the trial did not meet its primary progression-free survival end point. She also highlighted how disease biology and patient selection may influence outcomes when ADCs are moved into earlier lines of therapy, and outlined practical considerations for toxicity management and future trial design as the TROP2 ADC landscape continues to evolve.
asts, Spotify, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!

In today’s episode, Andrew Lipsky, MD, reviewed recent updates with BTK inhibitors in the chronic lymphocytic leukemia (CLL) treatment paradigm, including the clinical significance of the December 2025 FDA approval of pirtobrutinib (Jaypirca) in relapsed/refractory CLL and its effect on sequencing decisions for this disease. Dr Lipsky is an assistant professor of medicine at the Columbia University Medical Center in New York, New York.
In the exclusive interview, Dr Lipsky expanded on the positioning of this agent within the evolving CLL treatment paradigm and patient characteristics that may inform its use in practice; key efficacy and safety findings from a pooled analysis of the phase 3 BRUIN CLL-321 (NCT04666038) and phase 1/2 BRUIN LOXO-BTK-18001 (NCT03740529) studies presented during the 2025 ASH Annual Meeting; and the evolving role of BTK inhibitors as a whole in CLL management.

In today’s episode, the discussion features Adam Fox, MD, an assistant professor in the Department of Medicine at the College of Medicine at the Medical University of South Carolina in Charleston, and Cynthia A. Schandl, MD, PhD, medical director of clinical laboratories and director of the Division of Clinical Pathology in the College of Medicine at the Medical University of South Carolina, who examined the expanding role of biomarker testing and genomic profiling in non–small cell lung cancer (NSCLC) across disease stages

In today’s episode, the discussion features Sikander Ailawadhi, MD, and Beth Faiman, CNP, PhD, who provided clinical perspectives on the ongoing development of subcutaneous isatuximab-irfc (Sarclisa) administration via an on-body injector for patients with multiple myeloma. Dr Ailawadhi is a professor of medicine, a consultant in the Division of Hematology/Oncology in the Department of Internal Medicine, and a consultant in the Department of Cancer Biology at the Mayo Clinic Comprehensive Cancer Center in Jacksonville, Florida. Dr Faiman is a nurse practitioner in the Department of Hematology/Oncology at Cleveland Clinic and a member of the Cancer Prevention, Control and Population Research Program at the Case Comprehensive Cancer Center, both in Cleveland, Ohio.